Found this letter. Looks important. pic.twitter.com/3Ws154SGM4
— Martin Shkreli (e/acc) (@MartinShkreli) January 20, 2016
More trouble afoot for the pharmaceutical industry’s Voldemort: Former Turing Pharmaceuticals CEO Martin Shkreli has been subpoenaed by a U.S. congressional committee that is tasked with investigating rising drug costs, Bloomberg reports.
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
In a January 26 hearing, Turing Pharmaceuticals along with Valeant Pharmaceuticals will be investigated by the House Committee on Oversight and Government Reform. Bloomberg writes:
Shkreli is facing charges related to a separate former company and several hedge funds he used to run. He has maintained his innocence and pleaded not guilty. It hasn’t been clear if he would appear at the congressional hearing.
“We subpoenaed him,” MJ Henshaw, a spokeswoman for the committee, said in an e-mail. “The Committee expects him to comply with that subpoena.”
Henshaw said that Shkreli is the only person who’s been subpoenaed as part of the hearing.
This is turning into quite the comeuppance for the impish pharmaceutical executive. As this story develops, we’ll keep you updated.
Also worth a read: Matthew Herper’s excellent Forbes piece today, “Solving Pharma’s Shkreli problem.”